SSHA

Society of Sexual Health Advisers

Unite the union
  • About us
    • JOIN SSHA
    • Code of Professional Conduct
    • National Organising Professional Committee
    • National Organising Professional Committee Structure
    • Constitution and Rules
    • Council Reports
    • NPC ACCESS ONLY
  • News
  • Regions
    • London
    • North East, Yorkshire & Humberside
    • Ireland
    • Scotland
    • South West
    • East Midlands – VACANT
    • North West
    • South East
    • Wales
    • West Midlands
  • Resources
    • I Want To Be A Health Adviser
    • SSHA Manual
    • Conference Presentations
    • Competency Framework for Sexual Health Advisers
    • WeSSI: West Sussex Sexual Health Structured Interview
    • Research
    • Unite – Union
    • Publications
  • Jobs
    • Current Jobs
    • Sample Job Descriptions
  • Links
Home ยป NHS England has power to fund Prep HIV drug, court decides

NHS England has power to fund Prep HIV drug, court decides

November 11, 2016 By SSHA Leave a Comment

The Court of Appeal has ruled that the NHS in England has the power to fund a drug which prevents HIV infection in people at high risk of the virus.

NHS England had previously said that local authorities should provide the pre-exposure prophylaxis drug – known as Prep – because they are responsible for preventative health.

But the court insisted this fell within the remit of the NHS.

An estimated 14,000 people would be eligible for Prep in England.

Campaigners and the Local Government Association, which represents local authorities, said they were delighted by the decision.

NHS England said the judgment confirmed that it had the ability, but not the obligation, to fund Prep.

An NHS spokesman said it would now formally consider whether to fund the drug.

“Second, we will discuss with local authorities how NHS-funded Prep medication could be administered by the sexual health teams they commission.

“Third, we will immediately ask the drug manufacturer to reconsider its currently proposed excessively high pricing, and will also explore options for using generics.”

Prevention power

In August, the High Court told NHS England it could fund the drug because it was wrong to classify Prep as preventative, given that it acts in the body to treat infection.

This came after a successful challenge by the National Aids Trust (NAT) and other campaigners.

Deborah Gold, chief executive of NAT, said they were delighted that the Court of Appeal had confirmed the earlier judgement.

“HIV is a critical issue in the UK where over 4,000 people acquire HIV every year.

“Prep works, it saves money, and most importantly it has the power to prevent HIV acquisition for thousands of people, at the same time as beginning to end the HIV epidemic.

“This judgement brings that possibility one step closer.”

She said she hoped NHS England would now make “a balanced and evidence-based decision on Prep”.

Clarity of roles

Izzi Seccombe, chairman of the Local Government Association’s community wellbeing board, said treatment with Prep was clearly part of NHS England’s commissioning powers.

“We now hope this decision will provide much-needed clarity around the roles of councils and the NHS on prevention services.

She added: “It is time for NHS England to stop delaying and finally determine whether to commission this treatment, which could greatly reduce the risk of HIV infection.”

  • HIV drug row: A very modern dilemma for the NHS
  • Harry’s story: HIV drug ‘gave me confidence to trust’

What does Prep do?

Pre-exposure prophylaxis (or Prep for short) is a small, blue pill.

The pill works by protecting cells in the body and disabling the virus to stop it multiplying – should it enter the body.

Taking it once a day has been shown to reduce the risk of HIV infection by 86%.

It is currently used in the US, Canada, Australia and France to help protect gay men at the highest risk of contracting HIV.

Living with HIV

There are more than 100,000 people living with HIV in the UK and, statistically, gay men are the most at-risk group.

The average HIV prevalence in the UK is 2.3 per 1,000 population. However for gay men the rate jumps to 48.7 per 1,000.

Black African women are the second most at-risk group with a prevalence rate of 43.7 per 1,000.

Latest figures show there were 6,151 new diagnoses made in 2014, up from 6,032 the previous year, according to Public Health England.

10 November 2016
BBC NEWS

Filed Under: Featured, Latest SSHA News, Media Watch Tagged With: Court of Appeal, Deborah Gold, hiv, Izzi Seccombe, Local Government Association, NAT, national aids trust, NHS, nhs england, pep, phe, pre-exposure prophylaxis, prep, public health england

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About SSHA

The Society of Sexual Health Advisers (SSHA) is a UK national organisation with approximately 300 members out of an estimated 350 sexual health advisers in the country. It provides an opportunity for members to meet and work towards further professional development.

Recent Posts

  • Helping People to Reduce Sexual Health Risk: A Motivational Interviewing Approach February 28, 2023

Useful Links

  • BASHH
  • HPV Action
  • NAM
  • Public Health England
  • Public Health Scotland
  • Terence Higgins Trust
  • UNITE the Union

Copyright © 2023 · SSHA - Society of Sexual Health Advisers

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT